For the first time in history, a gene therapy can restore hearing to children born deaf — and it will cost their families nothing. The U.S. Food and Drug Administration approved Otarmeni on April 23, 2026 C.E., clearing the first-ever gene therapy for deafness caused by mutations in the OTOF gene. Biotechnology company Regeneron, which developed the treatment, announced it will offer the therapy free of charge to patients in the U.S.
At a glance
- Gene therapy for deafness: Otarmeni targets mutations in the OTOF gene, which affect up to 50 babies born each year in the U.S. and account for 1–3% of all cases of genetic hearing loss at birth.
- Clinical trial results: In a trial of 20 children, 16 showed meaningful hearing improvements around five months after treatment — and five of 12 followed for at least 11 months had hearing restored to essentially normal levels.
- Pricing decision: Rather than charging up to $4 million per patient — a price point that could have generated hundreds of millions in annual revenue — Regeneron chose to make the treatment free to U.S. patients.
How the treatment works
Children born with OTOF mutations lack a functional version of otoferlin, a protein that carries sound signals from the tiny hair cells of the inner ear to the brain. Without it, the auditory pathway is essentially broken at birth.
Otarmeni delivers a working copy of the OTOF gene directly into the inner ear through a surgical procedure similar to cochlear implantation. Once the gene is in place, the child’s body begins producing healthy otoferlin — and the connection between ear and brain can open.
The results in some children have been striking. One mother in the trial, whose 2-year-old son Miles received the therapy at 13 months, described the first sign it was working: he covered his ears when an ambulance passed. He had heard the siren. Today, he dances when music comes on and asks to be read dinosaur books.
A rare condition, a potentially lasting impact
OTOF mutations are uncommon. They affect only a small fraction of the roughly 1 in 500 children born with some degree of hearing loss in the U.S. each year, according to the National Institute on Deafness and Other Communication Disorders. But specialists say this approval carries meaning far beyond its narrow indication.
“There’s been an unbelievable interest in other forms of genetic deafness that are more common,” said Dr. Lawrence Lustig, chair of Otolaryngology-Head and Neck Surgery at Columbia University College of Physicians and Surgeons, who treated several children in the trial. Venture capital funding for gene therapies targeting more prevalent forms of hereditary deafness is already growing.
Dr. A. Eliot Shearer, an otolaryngologist at Boston Children’s Hospital and assistant professor at Harvard Medical School, helped run Regeneron’s trial. He described the change in children who received the therapy as “completely life-changing” — not an incremental shift, but a fundamental one.
Rethinking the price of rare disease medicine
Gene therapies for rare conditions often carry extraordinary price tags. Treatments approved in recent years have reached $2 million to $3 million per patient — and sometimes higher — as companies attempt to recover development costs from an extremely small pool of patients. Regeneron considered that model.
By Regeneron’s own estimates, charging up to $4 million per child could have generated $200 million to $400 million in annual revenue. The company decided not to do that. “We believe that we are a very different type of company,” said Dr. George Yancopoulos, Regeneron’s co-founder and president.
Yancopoulos also suggested the decision reflects a broader rethinking. With so many rare diseases collectively affecting large numbers of people, he questioned whether charging millions for each one is the right model. The experience of developing Otarmeni, he said, has helped lay groundwork for future therapies — with potentially different pricing strategies to come.
What remains uncertain
Researchers do not yet know how long the benefits of Otarmeni will last. The hope is that, because the gene is delivered directly to inner ear cells, the effects could be permanent — but long-term follow-up data are still limited. Most children in the trial have been followed for under two years.
The therapy also addresses only 1–3% of genetic hearing loss cases. Surgical costs for implantation are not covered by Regeneron’s free-pricing offer, meaning out-of-pocket expenses may still be a barrier for some families. And Regeneron has not yet committed to making the treatment free in other countries where it plans to seek approval.
Still, for the children and families who qualify, the approval marks something genuinely new. The FDA’s breakthrough therapy designation helped speed the review, and the agency’s new National Priority Voucher program flagged it as a treatment to fast-track. Doctors who have watched children hear music for the first time say the data speaks for itself.
Read more
For more on this story, see: CNN — FDA approves first gene therapy for inherited deafness
For more from Good News for Humankind, see:
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- Renewables now make up at least 49% of global power capacity
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
